The Thiosemicarbazone derivative of 4-chlorobenzaldehyde represents a promising compound with significant clinical relevance due to its broad-spectrum antimicrobial potential. In this study, two experimental approaches were employed to evaluate its efficacy against both fastidious and non-fastidious microorganisms. Minimum Inhibitory Concentration (MIC) was determined using a colorimetric assay, while antimicrobial susceptibility was assessed via the agar disc diffusion method. Data analysis was carried out using EUCAST and NCCLS guidelines to interpret zone diameters and MIC values. Graph Pad Prism software facilitated the comparison of inhibition zones and MIC values across various antibiotics. Additionally, WHONET 5.6 software was utilized to assess the epidemiological cut-off values (ECOFF) for the test compound, allowing for classification of bacterial isolates as susceptible, intermediate, or resistant. This integrative approach provided a robust assessment of the antimicrobial activity of the test compound in comparison with conventional antibiotics.
